entertainment -WSS

entertainment

author：leisure time 2025-10-02 18:48:12 - browse：61222

Fatty liver foregrounds arteries and veins surrounded by red blood cells — health coverage from STAT — Adobe

As drugmakers race to join the obesity drug market ignited by the approval of Wegovy and Zepbound, they’re not just competing on their drugs’ weight loss effects. They’re also competing on their products’ ability to treat a severe form of liver disease.

A new update of the STAT Obesity Drug Tracker shows that at least 23 — about one-fifth — of the 105 obesity treatments in development or on the market are also being investigated for metabolic dysfunction-associated steatohepatitis, the fatty liver disease known as MASH (and previously called NASH).

In this update, STAT has added a category — “other diseases investigated” — to show conditions beyond obesity for which a compound is being studied. Type 2 diabetes is the most common – it’s long been linked to obesity, and the latest GLP-1 treatments like Wegovy and Zepbound were initially developed as diabetes drugs. But behind diabetes, the next most common disease under investigation for obesity candidates is MASH.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Streamlined flu vaccines recommended by FDA advisory panel

hotspot

WSS

Ozempic has benefits for kidney disease as well as diabetes

Physicians and social media: If you see something, say something?

Florida health officials providing scant details on measles cases

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Colonoscopy prep: Liquid

State of the Union pitch: Bigger Medicare drug price negotiations

explore

entertainment

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Stem cell biologist probes earliest stages of human development

After affirmative action ruling, medical educators look to 'holistic review'

Longer MASH drug regimen improved liver, Akero study finds

Trump demands the U.S. pay no more for drugs than other countries … again

Harvard's David Sinclair gets blowback over aging

The high cost of giving birth even with insurance

Leading voice in opioid treatment defends methadone clinic system

What does generative AI mean for health care? We asked experts

Fetal cell organoids grown from amniotic fluid, study finds

focus

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Pregnant women don't need prenatal multivitamins, study concludes

Ancient Greek ideas underpin modern concepts of pregnancy

CVS Caremark has created a new ploy: the drug ‘rebate credit’

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Readout Newsletter: BridgeBio, Akero, and human embryo models

focus

hotspot

hotspot

hotspot